January, 22, 2008 -- According to a government filing, Shenzhen Chipscreen Biosciences Ltd. was paid $28 million as an upfront fee when it sold the ex-China rights to its cancer drug Chidamide to HUYA Bioscience International, LLC in October 2006. The out-licensing sale had been previously reported, but the price was not disclosed at the time. A histone deacetylase inhibitor (HDI), Chidamide is thought to regulate genetic activity including cell birth and death. More details...
